Why Tiziana Life Sciences Stock (TLSA) Is Climbing
Portfolio Pulse from Erica Kollmann
Tiziana Life Sciences, Ltd (NASDAQ:TLSA) stock is trading higher after the FDA cleared the Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer's disease. The company has received FDA clearance to advance its intranasal foralumab preparation into Phase 2 human clinical trials. The stock has seen heavy trading volume with more than 21.25 million shares traded in the session, compared to the stock's 100-day average of only 126,248 shares.
August 15, 2023 | 2:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tiziana Life Sciences' stock is trading higher after FDA clearance for Phase 2 trials of its intranasal foralumab in Alzheimer's disease. The stock has seen a significant increase in trading volume.
The FDA clearance for Phase 2 trials of Tiziana Life Sciences' intranasal foralumab in Alzheimer's disease is a significant milestone for the company. This news has led to a surge in the company's stock price and trading volume, indicating positive investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100